Author:
Hinze Claas,Thon Angelika
Publisher
Springer Berlin Heidelberg
Reference203 articles.
1. Abdul-Aziz R, Yu CY, Adler B, Bout-Tabaku S, Lintner KE, Moore-Clingenpeel M, Spencer CH (2017) Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM). Pediatr Rheumatol Online J 15(1):25. https://doi.org/10.1186/s12969-017-0154-4
2. Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30(6):1145–1156. https://doi.org/10.1007/s00198-019-04906-x
3. Aeschlimann FA, Fremond ML, Duffy D, Rice GI, Charuel JL, Bondet V, Saire E, Neven B, Bodemer C, Balu L, Gitiaux C, Crow YJ, Bader-Meunier B (2018) A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain J Neurol 141(11):e80. https://doi.org/10.1093/brain/awy255
4. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC, Group RIMS, Oddis CV (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740–749. https://doi.org/10.1002/art.38270
5. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27(10):2498–2503